Business Context and Reporting Period
This Form 8-K Current Report from Lightwave Logic, Inc. covers events occurring on November 1, 2011, with the report filed on November 7, 2011. The filing primarily addresses executive leadership changes within the company's technology division.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance data.
Material Changes
- Departure: Dr. David Eaton resigned as Chief Technology Officer (CTO) effective November 1, 2011. He will remain with the company as a non-executive scientific advisor.
- Appointment: Dr. Louis C. Glasgow was appointed as the new Chief Technology Officer effective November 1, 2011.
- Compensation: Dr. Glasgow's employment agreement includes a base salary of $104,000 per year and an option to purchase up to 150,000 shares of restricted common stock at a strike price of $0.63 per share.
- Vesting Schedule: The stock options vest quarterly over three years in equal installments of 12,500 shares per quarter, commencing February 1, 2012.
Outlook, Risks, and Management Commentary
Management highlighted Dr. Glasgow's extensive background, including his tenure as Director of Organic Technology at Corning, Inc. (2003–2010) and various roles at Dupont (1973–2001), culminating as Director of Innovation. The company confirmed there are no undisclosed arrangements regarding Dr. Glasgow's appointment and no family relationships with other directors or officers. A press release detailing the appointment was issued on November 1, 2011.
Investor Verification Checklist
- Verify the terms of Dr. Louis C. Glasgow's employment agreement (Exhibit 10.1).
- Review Dr. David Eaton's resignation letter (Exhibit 99.1) for any additional transition details.
- Confirm the impact of the CTO transition on ongoing product development and R&D timelines.
- Monitor the vesting schedule and potential dilution from the 150,000 stock options granted to Dr. Glasgow.